Multiple abstracts accepted for presentation at 2025 ASCO and AACR annual meetings underscore breadth of Bicycle® technology and potential of oncology pipeline Phase 1/2 Duravelo-3 trial for ...
Bicycle has acquired the RepU because it continually regenerates, providing a potentially sustainable supply of 212Pb, the ...
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary ...
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic ...
Execution of a 15-year contract including an option to renew with UK Nuclear Decommissioning Authority for access to up to 400 tonnes of reprocessed uranium (RepU), with the potential to deliver tens ...
Execution of a 15-year contract, including an option to renew with UK Nuclear Decommissioning Authority (Cumbria, UK) for access to up to 400 tonnes of reprocessed uranium (RepU), with the potential ...
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle ® molecules, for diseases that are underserved by existing therapeutics.
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary ...
Dose selection from Phase 2/3 Duravelo-2 trial and update on potential approval pathway expected in 1Q 2026 as company seeks feedback from multiple regulatory agencies Enhanced clinical leadership ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback